EUCTR2014-005172-28-IT进行中（未招募）1 期
COLCHICINE CARDIOVASCULAR OUTCOMES TRIAL (COLCOT) - COLCOT
MONTREAL HEART INSTITUTE0 个研究点目标入组 4,500 人开始时间: 2020年11月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males and females, at least 18 years of age , capable and willing to provide informed consent; Patient must have suffered a documented acute MI within the last 30 days; Patient must be treated according to national guidelines (including anti-platelet therapy, statin, renin-angiotensin-aldosterone system (RAAS) inhibitor (preferably angiotensinconverting- enzyme (ACE) inhibitor) and beta-blocker when indicated); Patient must have completed any planned percutaneous revascularization procedures associated with his/her qualifying MI; Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after study completion; Patient is judged to be in good general health as determined by the principal investigator; Patient must be able and willing to comply with the requirements of this study protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1000
排除标准
- •Patient with a poorly controlled medical condition, such as New York Heart Association Class III-IV heart failure, a left ventricular ejection fraction of less than 35%, recent stroke (within the past 3 months), or any other condition which, in the opinion of the investigator, would put the patient at risk if participating in the study; Patient with a type II index MI (secondary to ischemic imbalance); Patient with a prior coronary artery bypass graft within the past 3 years, or planned; Patient currently in cardiogenic shock or with hemodynamic instability; Patient with a history of cancer or lymphoproliferative disease within the last 3 years, other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix; Patient with inflammatory bowel disease (Crohn’s disease or ulcerative colitis) or patient with chronic diarrhea; Patient with pre-existent progressive neuromuscular disease or patient with CPK level > 3 times the upper limit of normal (unless due to MI, which is allowed) as measured within the past 30 days and determined to be non-transient through repeat testing; Patient with any of the following parameters as measured within the past 30 days, and determined to be non-transient through repeat testing: - hemoglobin < 115g/L, - white blood cell count < 3.0 X 109/L, - platelet count <110 X 109/L, - ALT > 3 times the upper limit of normal (ULN), - total bilirubin > 2 times ULN (unless due to Gilbert syndrome, which is allowed) - Creatinine > 2 times ULN; Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; Patient with a history of clinically significant drug or alcohol abuse in the last year; Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed); Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout). There is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment; Patient with a history of an allergic reaction or significant sensitivity to colchicine; Patient who has used an investigational chemical agent less than 30 days or 5 half-lives prior to the Screening visit (whichever is longer); Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study
研究者
相似试验
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-PTMontreal Heart Institute4,500
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-ESMontreal Heart Institute4,500
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-FRMontreal Heart Institute4,500
已完成
3 期
Colchicine Cardiovascular Outcomes Trial (COLCOT)Myocardial InfarctionCoronary Artery DiseaseNCT02551094Montreal Heart Institute4,745
招募中
3 期
The effect of Colchicine on Cardiovascular Outcomes in Acute Coronary Syndrome Study (The COLCARDIO-ACS Study)Acute coronary syndromeAtherosclerosisACTRN12616000400460niversity of Sydney3,000